UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 34

Sortiert nach

6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats

Drug metabolism and disposition, 2007-08, Vol.35 (8), p.1387

2007

Volltextzugriff (PDF)

Synthesis and structure–activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists

Bioorganic & medicinal chemistry letters, 2012-08, Vol.22 (15), p.4986-4989

2012

Volltextzugriff (PDF)

Synthesis and evaluation of succinoyl-caprolactam γ-secretase inhibitors

Bioorganic & medicinal chemistry letters, 2006-05, Vol.16 (9), p.2357-2363

2006

Volltextzugriff (PDF)

Dihydropyridopyrazinones and Dihydropteridinones as Corticotropin-Releasing Factor-1 Receptor Antagonists: Structure−Activity Relationships and Computational Modeling

Journal of medicinal chemistry, 2007-05, Vol.50 (9), p.2269-2272

2007

Volltextzugriff (PDF)

Synthesis, Structure−Activity Relationships, and in Vivo Properties of 3,4-Dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as Corticotropin-Releasing Factor-1 Receptor Antagonists

Journal of medicinal chemistry, 2004-11, Vol.47 (23), p.5783-5790

2004

Volltextzugriff (PDF)

Synthesis, Structure−Activity Relationships, and in Vivo Properties of 3,4-Dihydro-1 H -pyrido[2,3- b ]pyrazin-2-ones as Corticotropin-Releasing Factor-1 Receptor Antagonists

Journal of medicinal chemistry, 2004-11, Vol.47 (23), p.5783-5790

2004

Volltextzugriff (PDF)

P4-308: γ-secretase inhibitors differentially increase or decrease N-terminal variants of rat brain Aβ

Alzheimer's & dementia, 2006-07, Vol.2 (3), p.S607-S607

2006

Volltextzugriff (PDF)

Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder

Molecular psychiatry, 2015-11, Vol.20 (11), p.1397-1405

2015

Volltextzugriff (PDF)

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

The Lancet (British edition), 2022-02, Vol.399 (10326), p.741-755

2022

Volltextzugriff (PDF)

A Glutamate N -Methyl-d-Aspartate (NMDA) Receptor Subunit 2B-Selective Inhibitor of NMDA Receptor Function with Enhanced Potency at Acidic pH and Oral Bioavailability for Clinical Use

The Journal of pharmacology and experimental therapeutics, 2021-10, Vol.379 (1), p.41

2021

Volltextzugriff (PDF)

Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials

Ophthalmology (Rochester, Minn.), 2024-06, Vol.131 (6), p.708

2024

Volltextzugriff (PDF)

Pharmacodynamics of selective inhibition of γ-secretase by avagacestat

The Journal of pharmacology and experimental therapeutics, 2013-03, Vol.344 (3), p.686

2013

Volltextzugriff (PDF)

Presenilin-1 and -2 Are Molecular Targets for γ-Secretase Inhibitors

The Journal of biological chemistry, 2000-11, Vol.275 (44), p.34086-34091

2000

Volltextzugriff (PDF)

Binding sites of gamma-secretase inhibitors in rodent brain: distribution, postnatal development, and effect of deafferentation

The Journal of neuroscience, 2004-03, Vol.24 (12), p.2942-2952

2004

Volltextzugriff (PDF)

Signal Peptide Peptidase and γ-Secretase Share Equivalent Inhibitor Binding Pharmacology

The Journal of biological chemistry, 2007-12, Vol.282 (51), p.36829-36836

2007

Volltextzugriff (PDF)

Characterization of [125I]sauvagine binding to CRH2 receptors: membrane homogenate and autoradiographic studies

The Journal of pharmacology and experimental therapeutics, 1998-07, Vol.286 (1), p.459

1998

Volltextzugriff (PDF)

Detection and localization of early- and late-stage cancers using platelet RNA

Cancer cell, 2022-09, Vol.40 (9), p.999-1009.e6

2022

Volltextzugriff (PDF)

The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist

Bioorganic & medicinal chemistry, 2000-01, Vol.8 (1), p.181-189

2000

Volltextzugriff (PDF)

Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice

The Journal of pharmacology and experimental therapeutics, 2007-10, Vol.323 (1), p.102

2007

Volltextzugriff (PDF)

Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6h-purin-6-one and 3,7-dihydro-1h-purine-2,6-dione derivatives as corticotropin-releasing factor(1) receptor antagonists

Journal of medicinal chemistry, 2004-09, Vol.47 (19), p.4741

2004

Volltextzugriff (PDF)

Signal Peptide Peptidase and Î³-Secretase Share Equivalent Inhibitor Binding Pharmacology

The Journal of biological chemistry, 2007-12, Vol.282 (51), p.36829

2007

Volltextzugriff (PDF)

2-Fluoro-4-pyridinylmethyl Analogues of Linopirdine as Orally Active Acetylcholine Release-Enhancing Agents with Good Efficacy and Duration of Action

Journal of medicinal chemistry, 1998-11, Vol.41 (23), p.4615-4622

1998

Volltextzugriff (PDF)

Imidazo[4,5- b]pyridines as corticotropin releasing factor receptor ligands

Bioorganic & medicinal chemistry letters, 2003-01, Vol.13 (1), p.125-128

2003

Volltextzugriff (PDF)

Imidazo[4,5- c]pyridines as corticotropin releasing factor receptor ligands

Bioorganic & medicinal chemistry letters, 2003-01, Vol.13 (1), p.129-131

2003

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(34)

Sprache

Englisch
(34)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Animals
(21)
Pharmacology & Pharmacy
(17)
Rats
(16)
Male
(14)
Biological And Medical Sciences
(13)
Humans
(13)
Chemistry, Medicinal
(12)
Medical Sciences
(12)
Pharmacology. Drug Treatments
(10)
Receptors, Corticotropin-Releasing Hormone - Metabolism
(8)
Structure-Activity Relationship
(8)
Dogs
(7)
Receptors, Corticotropin-Releasing Hormone - Antagonists & Inhibitors
(7)
Cell Line
(6)
Chemistry
(6)
Chemistry, Organic
(6)
Female
(6)
Middle Aged
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats

Synthesis and structure–activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists

Synthesis and evaluation of succinoyl-caprolactam γ-secretase inhibitors

Dihydropyridopyrazinones and Dihydropteridinones as Corticotropin-Releasing Factor-1 Receptor Antagonists: Structure−Activity Relationships and Computational Modeling

Synthesis, Structure−Activity Relationships, and in Vivo Properties of 3,4-Dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as Corticotropin-Releasing Factor-1 Receptor Antagonists

Synthesis, Structure−Activity Relationships, and in Vivo Properties of 3,4-Dihydro-1 H -pyrido[2,3- b ]pyrazin-2-ones as Corticotropin-Releasing Factor-1 Receptor Antagonists

P4-308: γ-secretase inhibitors differentially increase or decrease N-terminal variants of rat brain Aβ

Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

A Glutamate N -Methyl-d-Aspartate (NMDA) Receptor Subunit 2B-Selective Inhibitor of NMDA Receptor Function with Enhanced Potency at Acidic pH and Oral Bioavailability for Clinical Use

Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials

Pharmacodynamics of selective inhibition of γ-secretase by avagacestat

Presenilin-1 and -2 Are Molecular Targets for γ-Secretase Inhibitors

Binding sites of gamma-secretase inhibitors in rodent brain: distribution, postnatal development, and effect of deafferentation

Signal Peptide Peptidase and γ-Secretase Share Equivalent Inhibitor Binding Pharmacology

Characterization of [125I]sauvagine binding to CRH2 receptors: membrane homogenate and autoradiographic studies

Detection and localization of early- and late-stage cancers using platelet RNA

The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist

Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice

Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6h-purin-6-one and 3,7-dihydro-1h-purine-2,6-dione derivatives as corticotropin-releasing factor(1) receptor antagonists

Signal Peptide Peptidase and Î³-Secretase Share Equivalent Inhibitor Binding Pharmacology

2-Fluoro-4-pyridinylmethyl Analogues of Linopirdine as Orally Active Acetylcholine Release-Enhancing Agents with Good Efficacy and Duration of Action

Imidazo[4,5- b]pyridines as corticotropin releasing factor receptor ligands

Synthesis, Corticotropin-Releasing Factor Receptor Binding Affinity, and Pharmacokinetic Properties of Triazolo-, Imidazo-, and Pyrrolopyrimidines and -pyridines

Imidazo[4,5- c]pyridines as corticotropin releasing factor receptor ligands

Suchergebnisse filtern